This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Weintraub, W. S. Search for Related Content PubMed PubMed Citation Articles by Weintraub, W. S.

Economic impact of GPIIB/IIIA blockade after high-risk angioplasty

Results from the restore trial

William S. Weintraub, MD^*, Steven Culler, PhD, Stephen J. Boccuzzi, PhD^||, John R. Cook, PhD^||, Andrzej S. Kosinski, PhD, David J. Cohen, MD, Joy Burnette, RN^* for the RESTORE Trial Study Group

^* Emory Center for Outcomes Research, Division of Cardiology, Department of Medicine, Atlanta, Georgia, USA
Department of Health Policy and Management, Atlanta, Georgia, USA
Department of Biostatistics, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA
Beth Israel Hospital, Harvard University School of Medicine, Boston, Massachusetts, USA
^|| Outcomes Research and Management, Health Economics Statistics, Merck & Co., Inc., Whitehouse Station, New Jersey, USA

View larger version (17K): [in a new window]   Figure 1 Cumulative costs in the two treatment arms in the cost substudy patients.

View larger version (16K): [in a new window]   Figure 2 Cumulative costs in the two treatment arms in all U.S. patients.

View larger version (15K): [in a new window]   Figure 3 Cumulative costs over time in the two treatment arms in all U.S. patients.